Log inHyaluronic acid nanogel
Hyaluronic acid nanogel
Sonanos™
Novel pharmaceutical excipient primarily
for injection formulation
Our rationale for Sonanos™
To respond to unmet medical needs, the pharmaceuticals industry has recently attempted to develop drugs using various molecular modalities that can access targets that have previously been difficult to reach. Among such molecular modalities, there are many APIs that have problems such as poor water solubility, limited options to modulate release profiles, and toxicity, and they are difficult to develop into pharmaceuticals with current technology.
As a materials manufacturer, we strive to contribute to the development of new pharmaceuticals with high technical hurdles. We seek to achieve this through the new excipient, hyaluronic acid nanogel(Sonanos™), which has high biocompatibility and excellent functionality. Sonanos™ supports a wide range of modalities as a DDS material, and has various functions such as sustained release and solubility enhancement. We aim to contribute to the improvement of patients’ quality of life by developing pharmaceutical formulations that cannot be made with existing formulation technology.
As a solutions partner that expands the possibilities of DDS formulation and thus enabling our customers to truly “deliver your potential,” we will continue to meet their needs and contribute to the health and daily lives of people around the world.
-
Technical documents
-
Quality/regulatory documents